



November 15, 2019

Novartis Pharma AG
CH-4002, Basel, Switzerland

Reference: EudraCT 2015-004440-19/ Novartis Protocol ID CLAM320B2202

A 30-month multicenter, phase 2b/3, randomized, open label trial to evaluate the efficacy and safety of clofazimine administered orally in addition to background regimen compared to background regimen alone in the treatment of patients with multidrug-resistant pulmonary tuberculosis

Trial CLAM320B2202 was cancelled with no patient enrollment and as such, no results will be reported.

Due to a flaw in the EudraCT system, the Global End of Trial date in the system only was changed to July 1, 2012 to allow upload of this letter to notify the public that this trial was cancelled and no patients were enrolled.